ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MNOV vs MRK // NET PROFIT MARGIN

Medicinova Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: MNOV 2 — MRK 8
▲ NET PROFIT MARGIN LEADER: MNOV
net-margins
68.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNOV VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MNOV MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -14.24% 3.42% -17.66 MRK /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin ACTIVE 68.00% 28.10% +39.90 MNOV /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.19 -4.99 MRK /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.4 51.7 -13.27 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 5.3x 18.4x -13.10 MNOV /forward-pe <GO>
Enterprise Scale & Market Cap $68.9M $361.02B -$360.95B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MNOV REV MRK REV MNOV GROSS % MRK GROSS % MNOV FCF MRK FCF
FY 2025 $409.7K $65.01B — 74.8% -$9.8M $12.36B
FY 2024 $0 $64.17B — 76.3% -$10.6M $18.10B
FY 2023 $1.0M $60.12B — — -$7.4M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNOV // BETA —
MRK // BETA 0.92